Where to go with new expensive treatments in NSCLC
1998

New Treatments for Non-Small-Cell Lung Cancer

Sample size: 1000 publication Evidence: moderate

Author Information

Author(s): A Webb, MER O'Brien

Primary Institution: The Royal Marsden Hospital

Hypothesis

How do we make progress in the treatment of non-small-cell lung cancer with new expensive treatments?

Conclusion

New combinations of treatments for non-small-cell lung cancer show promising response rates but require further validation through larger studies.

Supporting Evidence

  • Two studies showed a high response rate of 54% and 67% with new drug combinations.
  • New treatments are significantly more expensive than previous regimens.
  • Current drug budgets are insufficient to cover the costs of new treatments.

Takeaway

Doctors are trying new medicines to help people with lung cancer, but they need to make sure these medicines really work before using them a lot.

Methodology

Review of multiple studies on new drug combinations for non-small-cell lung cancer.

Potential Biases

Potential bias in reporting due to the pharmaceutical industry's influence on drug development and pricing.

Limitations

The review highlights that many studies are phase II and results must be interpreted with caution until phase III trials are completed.

Participant Demographics

Patients with advanced non-small-cell lung cancer.

Statistical Information

P-Value

0.048

Confidence Interval

95% CI 16-25

Statistical Significance

p<0.05

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication